Impilo invests in Swedish HIV diagnostics company Cavidi

Impilo has invested in a 29% stake in Cavidi AB, an Uppsala-based diagnostics company focused on HIV Viral Load monitoring. Cavidi has developed a new fully automated viral load diagnostic platform. This platform, Ziva™, aims to meet the need for cost-effective monitoring in high-disease burden countries. 

“We launched development of the Ziva platform with a loan from the European Investment Bank, our first institutional capital.  We have now largely completed Ziva development and established a distribution agreement with a top 10 global diagnostic company. With this financing, we have secured the growth equity to support Ziva’s launch. We are pleased to welcome Impilo as one of our major owners,” says John Reisky de Dubnic CEO at Cavidi.

“Impilo has a long-term approach to building value and aim to produce lasting positive effects in the healthcare sector. We believe that the success of the companies we invest in depends on their contribution to a positive development of society through improved products and services. Impilo is therefore a good fit for Cavidi”, says Fredrik Strömholm, Partner at Impilo.

Veronica Byfield Sköld, Partner at Impilo, continues, “Cavidi’s focus on delivering technology that enables healthcare systems to implement the WHO guidelines on how to better monitor HIV, we believe will provide tremendous value. Our objective is that our contribution will help Cavidi grow to become a strong diagnostics company with global impact on HIV/AIDS containment”.

Cavidi’s Board of Directors now consists of Chairman Erik Walldén, former CEO of Gyros AB, Affibody Holding AB, Biacore International AB, and Pyrosequencing AB (now Biotage AB); Ernst Westman, former CEO of Boule Diagnostics AB; Cynthia Collins, former CEO of Human Longevity, GE Healthcare In Vitro Diagnostics, Research & Applied Markets, and Cell Therapy, GenVec Inc, and with extensive experience from Beckman Coulter, Baxter Healthcare and Abbott Laboratories; David Summa, former CEO of start-ups Mendel, Acumen, and Kinestral, and with a background from McKinsey, Monsanto and P&G; and Impilo partners Fredrik Strömholm and Veronica Byfield Sköld.

Impilo, an investment company focusing on Nordic healthcare companies and established in 2017, has more than SEK 3bn in capital from leading Nordic and international investors. Cavidi is the company’s third investment to date, following the investments in Ferrosan Medical Devices, a Danish company active in the field of hemostatic products used to stop bleeding during surgical procedures, and in NutraQ, a Norwegian company offering nutritional supplements, medical devices and skin care products directly to consumers through subscription solutions.

For more information

Fredrik Strömholm, partner
+46 76-115 10 65
fredrik.stromholm@impilo.se

_____________________________________________________________

Impilo is an investment company focused on investments in Nordic healthcare companies active in the pharmaceutical, medical devices, care services and other health related areas. Impilo’s perspective is that the portfolio companies must contribute to a positive development in their field and thus society in order to be successful longer term. 

Tags:

About Us

We are an investment company with an approach based on the premise that we must invest and drive development so as to produce a lasting, positive effect on the future of our investee companies, society at large and ourselves. A premise that also benefits our investment success, since it forces us to understand each business and reduce risks, and thereby develop our ability to act as progressive owners. We invest in people’s opportunities to enjoy healthier lives in the future.

Subscribe

Documents & Links